Mora Nova

Mora Nova is a South Korean biotechnology company focused on developing first-in-class therapeutics for metabolic diseases by leveraging mitophagy-inducing small molecules. The company's primary research centers on restoring mitochondrial function to treat chronic conditions such as metabolic dysfunction-associated steatohepatitis (MASH), obesity, and type 2 diabetes. Its lead program, MOP-007, is an orally available small molecule designed to stimulate mitochondrial autophagy, thereby improving metabolic health and reducing systemic inflammation. Founded by experts in endocrinology and metabolism, Mora Nova utilizes a proprietary platform to identify novel compounds that address the root causes of metabolic syndrome.